Vanguard Group Inc. Sells 39,790 Shares of ICU Medical, Inc. $ICUI

Key Points

• Vanguard Group Inc. has reduced its stake in ICU Medical, Inc. by 1.5%, selling 39,790 shares and now owning approximately 10.74% of the company worth $366,906,000.
• Several hedge funds have recently increased their holdings in ICU Medical, with a notable 23% increase in shares owned by Blue Trust Inc. during the 1st quarter.
• ICU Medical reported earnings of $2.10 per share for the latest quarter, exceeding expectations, despite a 8% decline in revenue compared to the previous year.

Vanguard Group Inc. lessened its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 1.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,642,275 shares of the medical instruments supplier's stock after selling 39,790 shares during the period. Vanguard Group Inc. owned approximately 10.74% of ICU Medical worth $366,906,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ICUI. Xponance Inc. boosted its stake in ICU Medical by 5.3% during the 1st quarter. Xponance Inc. now owns 1,714 shares of the medical instruments supplier's stock valued at $238,000 after purchasing an additional 86 shares during the last quarter. LPL Financial LLC boosted its stake in ICU Medical by 2.0% during the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier's stock valued at $747,000 after purchasing an additional 93 shares during the last quarter. Blue Trust Inc. boosted its stake in ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 150 shares during the last quarter. GAMMA Investing LLC boosted its stake in ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 153 shares during the last quarter. Finally, Vise Technologies Inc. boosted its stake in ICU Medical by 7.1% during the 4th quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier's stock valued at $411,000 after purchasing an additional 176 shares during the last quarter. Institutional investors own 96.10% of the company's stock.

ICU Medical Stock Performance

Shares of ICUI stock traded down $1.61 on Thursday, reaching $121.75. The stock had a trading volume of 225,717 shares, compared to its average volume of 376,131. The stock has a market cap of $3.01 billion, a P/E ratio of -80.10 and a beta of 0.88. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The company has a 50 day simple moving average of $127.24 and a 200 day simple moving average of $137.28.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, topping analysts' consensus estimates of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $543.57 million for the quarter, compared to analysts' expectations of $543.33 million. During the same period last year, the firm earned $1.56 EPS. ICU Medical's revenue for the quarter was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities research analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

ICUI has been the topic of several recent analyst reports. Piper Sandler initiated coverage on ICU Medical in a research note on Friday, August 15th. They set an "overweight" rating and a $145.00 target price on the stock. Raymond James Financial dropped their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded ICU Medical from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $179.00.

Insiders Place Their Bets

In related news, CEO Vivek Jain bought 21,929 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average cost of $112.84 per share, with a total value of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Christian B. Voigtlander sold 4,985 shares of the firm's stock in a transaction on Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the completion of the transaction, the chief operating officer directly owned 6,088 shares in the company, valued at approximately $782,308. This represents a 45.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.